These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34099204)

  • 1. Study of treatment outcomes of multidrug-resistant tuberculosis under programmatic conditions and factors influencing the outcomes in Hyderabad District.
    Kandi S; K TK; Kandi SR; Mathur N; D CD; Adepu R
    Indian J Tuberc; 2021 Jul; 68(3):379-383. PubMed ID: 34099204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis Pathways to Care and Transmission of Multidrug Resistance in India.
    Atre SR; Jagtap JD; Faqih MI; Dumbare YK; Sawant TU; Ambike SL; Bhawalkar JS; Bharaswadkar SK; Jogewar PK; Adkekar RS; Hodgar BP; Jadhav V; Mokashi ND; Golub JE; Dixit A; Farhat MR
    Am J Respir Crit Care Med; 2022 Jan; 205(2):233-241. PubMed ID: 34706203
    [No Abstract]   [Full Text] [Related]  

  • 4. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and Other Risk Factors for Multi-drug Resistant Tuberculosis in a Mexican Population with Pulmonary Tuberculosis: Case Control Study.
    Gómez-Gómez A; Magaña-Aquino M; López-Meza S; Aranda-Álvarez M; Díaz-Ornelas DE; Hernández-Segura MG; Salazar-Lezama MÁ; Castellanos-Joya M; Noyola DE
    Arch Med Res; 2015 Feb; 46(2):142-8. PubMed ID: 25704633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study.
    Diallo A; Diallo BD; Camara LM; Kounoudji LAN; Bah B; N'Zabintawali F; Carlos-Bolumbu M; Diallo MH; Sow OY
    BMC Infect Dis; 2020 Apr; 20(1):315. PubMed ID: 32345228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.
    Nair SA; Raizada N; Sachdeva KS; Denkinger C; Schumacher S; Dewan P; Kulsange S; Boehme C; Paramsivan CN; Arinaminpathy N
    PLoS One; 2016; 11(2):e0150054. PubMed ID: 26918818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Xpert MTB/RIF assay on multidrug-resistant tuberculosis treatment outcomes in a health district in South Africa.
    Mahwire TC; Zunza M; Marukutira TC; Naidoo P
    S Afr Med J; 2019 Mar; 109(4):259-263. PubMed ID: 31084692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly successful treatment outcome of multidrug-resistant and genetic diversity of multidrug-resistant Mycobacterium tuberculosis strains in Rwanda.
    Muvunyi CM; Ngabonziza JCS; Uwimana I; Harelimana JD; Mucyo Y; Sebatunzi OR; Muvunyi TZ; Seruyange E; Masaisa F; Mazarati JB; Gasana M
    Trop Med Int Health; 2019 Jul; 24(7):879-887. PubMed ID: 31066112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
    Abebe G; Abdissa K; Abdissa A; Apers L; Agonafir M; de-Jong BC; Colebunders R
    BMC Res Notes; 2012 May; 5():225. PubMed ID: 22574696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India?
    Dave P; Vadera B; Kumar AM; Chinnakali P; Modi B; Solanki R; Patel P; Patel P; Pujara K; Nimavat P; Shah A; Bharaswadkar S; Rade K; Parmar M; Nair SA
    PLoS One; 2015; 10(4):e0121996. PubMed ID: 25874545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India.
    Jain A; Singh PK; Chooramani G; Dixit P; Malhotra HS
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):870-5. PubMed ID: 27287637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.
    Lorent N; Kong C; Kim T; Sam S; Thai S; Colebunders R; Rigouts L; Lynen L
    Int J Tuberc Lung Dis; 2015 Dec; 19(12):1528-35. PubMed ID: 26614197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study.
    Htun YM; Khaing TMM; Aung NM; Yin Y; Myint Z; Aung ST; Soonthornworasiri N; Silachamroon U; Kasetjaroen Y; Kaewkungwal J
    PLoS One; 2018; 13(12):e0209932. PubMed ID: 30596734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.